Ovid Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Ovid Therapeutics

08/05/2023 14:03

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 17 cents per share.
    * Revenue fell 95.4% to $66.16 thousand from a year ago;
analysts
expected $18.67 thousand. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was a
loss
of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 10% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Ovid Therapeutics Inc shares had risen by 40.7% this
quarter and
gained 95.2% so far this year.
    * The company reported a quarterly loss of $13.36 million.
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $4.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 01:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.17          -0.19          Missed
 Dec. 31 2022      -0.18          -0.16          Beat
 Sep. 30 2022      -0.21          -0.17          Beat
 Jun. 30 2022      -0.25          -0.21          Beat